Download PDF
Digestive Disease Interventions 2019; 03(02): 107-116
DOI: 10.1055/s-0039-1691813
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Ablation in Primary Liver Tumors

D. Putzer
1   Department of Radiology, Medical University Innsbruck, Innsbruck, Austria
,
P. Schullian
1   Department of Radiology, Medical University Innsbruck, Innsbruck, Austria
,
R. Bale
1   Department of Radiology, Medical University Innsbruck, Innsbruck, Austria
› Author Affiliations
Further Information

Publication History

22 December 2018

16 April 2019

Publication Date:
03 June 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Minimal invasive thermal ablation techniques have a key role in the treatment regimen of primary liver tumors. These relatively low-risk procedures are established in nonresectable liver tumors and even challenge the surgical approach, which is regarded as first-line treatment in eligible patients.

The location and size of the liver tumor, the applied ablation, and guidance technique are crucial for treatment outcome. The confirmation of an adequate ablation zone including sufficient tumor overlap and a safety margin (A0 ablation analogous to R0 resection) is crucial to minimize local recurrence rates and improve survival. A variety of different ablation devices is available. The outcome of conventional computed tomography- or ultrasound-guided thermal ablation in small lesions is well comparable to surgery. However, in liver lesions with large diameter overlapping ablation zones are required to ensure an adequate ablation margin. Therefore, stereotactic techniques in combination with a multiple needle approach, three-dimensional trajectory planning, and image fusion for intraoperative treatment evaluation have been successfully introduced.

Keywords

radiofrequency ablation - liver tumor treatment - percutaneous tumor treatment - interventional oncology - stereotaxy
 

  • References

  • 1 Galle PR, Forner A, Llovet JP. , et al; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    CrossrefPubMedGoogle Scholar
  • 2 Heimbach JK, Kulik LM, Finn RS. , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
    CrossrefPubMedGoogle Scholar
  • 3 Omata M, Cheng AL, Kokudo N. , et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11 (04) 317-370
    CrossrefPubMedGoogle Scholar
  • 4 Holzwanger DJ, Madoff DC. Role of interventional radiology in the management of hepatocellular carcinoma: current status. Linchuang Zhongliuxue Zazhi 2018; 7 (05) 49
    PubMedGoogle Scholar
  • 5 Abdelaziz AO, Nabeel MM, Elbaz TM. , et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol 2015; 50 (04) 479-484
    CrossrefPubMedGoogle Scholar
  • 6 Liu Y, Zheng Y, Li S, Li B, Zhang Y, Yuan Y. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin Radiol 2013; 68 (01) 21-26
    CrossrefPubMedGoogle Scholar
  • 7 Zhang NN, Lu W, Cheng XJ, Liu JY, Zhou YH, Li F. High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence. Clin Radiol 2015; 70 (11) 1237-1243
    CrossrefPubMedGoogle Scholar
  • 8 Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60 (125) 1131-1135
    PubMedGoogle Scholar
  • 9 Pearson AS, Izzo F, Fleming RY. , et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999; 178 (06) 592-599
    CrossrefPubMedGoogle Scholar
  • 10 Dollinger M, Beyer LP, Haimerl M. , et al. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience. Diagn Interv Radiol 2015; 21 (06) 471-475
    CrossrefPubMedGoogle Scholar
  • 11 Sala M, Llovet JM, Vilana R. , et al; Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40 (06) 1352-1360
    CrossrefPubMedGoogle Scholar
  • 12 Lam VW, Ng KK, Chok KS. , et al. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol 2008; 15 (03) 782-790
    CrossrefPubMedGoogle Scholar
  • 13 Lu DS, Yu NC, Raman SS. , et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234 (03) 954-960
    CrossrefPubMedGoogle Scholar
  • 14 Hocquelet A, Trillaud H, Frulio N. , et al. Three-dimensional measurement of hepatocellular carcinoma ablation zones and margins for predicting local tumor progression. J Vasc Interv Radiol 2016; 27 (07) 1038-1045.e2
    CrossrefPubMedGoogle Scholar
  • 15 Tapper EB, Catana AM, Sethi N. , et al. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer 2016; 122 (06) 852-858
    CrossrefPubMedGoogle Scholar
  • 16 Nakazawa T, Kokubu S, Shibuya A. , et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188 (02) 480-488
    CrossrefPubMedGoogle Scholar
  • 17 Hung HH, Chiou YY, Hsia CY. , et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9 (01) 79-86
    CrossrefPubMedGoogle Scholar
  • 18 Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010; 51 (04) 1284-1290
    CrossrefPubMedGoogle Scholar
  • 19 Widmann G, Schullian P, Bale R. Radiofrequenzablation des hepatozellulären Karzinoms. Wien Med Wochenschr 2013; 163 (5-6): 132-136
    CrossrefPubMedGoogle Scholar
  • 20 Bale R, Widmann G. Navigated CT-guided interventions. Minim Invasive Ther Allied Technol 2007; 16 (04) 196-204
    CrossrefPubMedGoogle Scholar
  • 21 Samim M, Molenaar IQ, Seesing MF. , et al. The diagnostic performance of 18F-FDG PET/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases: a systematic review and meta-analysis. Surg Oncol 2017; 26 (01) 37-45
    CrossrefPubMedGoogle Scholar
  • 22 Bale R, Widmann G, Haidu M. Stereotactic radiofrequency ablation. Cardiovasc Intervent Radiol 2011; 34 (04) 852-856
    CrossrefPubMedGoogle Scholar
  • 23 Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol 2010; 75 (01) 32-36
    CrossrefPubMedGoogle Scholar
  • 24 Bale R, Widmann G, Schullian P. , et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol 2012; 22 (04) 930-937
    CrossrefPubMedGoogle Scholar
  • 25 Haidu M, Dobrozemsky G, Schullian P. , et al. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol 2012; 35 (05) 1074-1082
    CrossrefPubMedGoogle Scholar
  • 26 Bale R, Schullian P, Eberle G. , et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers. Hepatology 2018; doi: 10.1002/hep.30406
    PubMedGoogle Scholar
  • 27 Calandri M, Mauri G, Yevich S. , et al. Fusion imaging and virtual navigation to guide percutaneous thermal ablation of hepatocellular carcinoma: a review of the literature. Cardiovasc Intervent Radiol 2019; 42 (05) 639-647
    CrossrefPubMedGoogle Scholar
  • 28 Mazzaferro V, Battiston C, Perrone S. , et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240 (05) 900-909
    CrossrefPubMedGoogle Scholar
  • 29 Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis. World J Gastroenterol 2014; 20 (29) 10174-10182
    CrossrefPubMedGoogle Scholar
  • 30 Oshowo A, Gillams AR, Lees WR, Taylor I. Radiofrequency ablation extends the scope of surgery in colorectal liver metastases. Eur J Surg Oncol 2003; 29 (03) 244-247
    CrossrefPubMedGoogle Scholar
  • 31 Mulier S, Mulier P, Ni Y. , et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002; 89 (10) 1206-1222
    CrossrefPubMedGoogle Scholar
  • 32 Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226 (02) 441-451
    CrossrefPubMedGoogle Scholar
  • 33 Choi D, Lim HK, Kim MJ. , et al. Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. AJR Am J Roentgenol 2005; 184 (06) 1860-1867
    CrossrefPubMedGoogle Scholar
  • 34 Schullian P, Weiss H, Klaus A. , et al. Laparoscopic liver packing to protect surrounding organs during thermal ablation. Minim Invasive Ther Allied Technol 2014; 23 (05) 294-301
    CrossrefPubMedGoogle Scholar
  • 35 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8 (06) 429-436
    CrossrefPubMedGoogle Scholar
  • 36 Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol 2018; 68 (04) 783-797
    CrossrefPubMedGoogle Scholar
  • 37 Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004; 127 (06) 1714-1723
    CrossrefPubMedGoogle Scholar
  • 38 Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54 (08) 1151-1156
    CrossrefPubMedGoogle Scholar
  • 39 Shiina S, Teratani T, Obi S. , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129 (01) 122-130
    CrossrefPubMedGoogle Scholar
  • 40 Lencioni RA, Allgaier HP, Cioni D. , et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228 (01) 235-240
    CrossrefPubMedGoogle Scholar
  • 41 Brunello F, Veltri A, Carucci P. , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43 (06) 727-735
    CrossrefPubMedGoogle Scholar
  • 42 Chen MS, Li JQ, Zheng Y. , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (03) 321-328
    CrossrefPubMedGoogle Scholar
  • 43 Feng K, Yan J, Li X. , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57 (04) 794-802
    CrossrefPubMedGoogle Scholar
  • 44 Fang Y, Chen W, Liang X. , et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (01) 193-200
    CrossrefPubMedGoogle Scholar
  • 45 Huang J, Yan L, Cheng Z. , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252 (06) 903-912
    CrossrefPubMedGoogle Scholar
  • 46 Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer 2003; 97 (12) 3027-3035
    CrossrefPubMedGoogle Scholar
  • 47 Lee YH, Hsu CY, Chu CW. , et al. Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses. J Clin Gastroenterol 2015; 49 (03) 242-249
    CrossrefPubMedGoogle Scholar
  • 48 Peng ZW, Lin XJ, Zhang YJ. , et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262 (03) 1022-1033
    CrossrefPubMedGoogle Scholar
  • 49 Pompili M, Saviano A, de Matthaeis N. , et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol 2013; 59 (01) 89-97
    CrossrefPubMedGoogle Scholar
  • 50 Guo W, He X, Li Z, Li Y. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. surgical resection (SR) on survival outcome of early hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2015; 62 (139) 710-714
    PubMedGoogle Scholar
  • 51 Lan T, Chang L, Rahmathullah MN, Wu L, Yuan YF. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore) 2016; 95 (15) e3185
    PubMedGoogle Scholar
  • 52 Kariyama K, Wakuta A, Nishimura M. , et al. Percutaneous radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Oncology 2015; 89 (Suppl. 02) 19-26
    CrossrefPubMedGoogle Scholar
  • 53 Mazzaferro V, Regalia E, Doci R. , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 54 Vogel A, Cervantes A, Chau I. , et al; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Supplement _4): iv238-iv255
    CrossrefPubMedGoogle Scholar
  • 55 Mazzaferro V, Llovet JM, Miceli R. , et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 56 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg 2017; 402 (06) 863-871 ; Epub ahead of print
    CrossrefPubMedGoogle Scholar
  • 57 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. ; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (01) e11-e22
    CrossrefPubMedGoogle Scholar
  • 58 Yao FY, Mehta N, Flemming J. , et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 59 Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37 (06) 806-813
    CrossrefPubMedGoogle Scholar
  • 60 Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24 (02) 115-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Simo KA, Halpin LE, McBrier NM. , et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review. J Surg Oncol 2016; 113 (01) 62-83
    CrossrefPubMedGoogle Scholar
  • 62 Khan SA, Davidson BR, Goldin RD. , et al; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61 (12) 1657-1669
    CrossrefPubMedGoogle Scholar
  • 63 Park HM, Yun SP, Lee EC. , et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol 2016; 23 (13) 4392-4400
    CrossrefPubMedGoogle Scholar
  • 64 Coelen RJS, Vogel JA, Vroomen LGPH. , et al. Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility study protocol. BMJ Open 2017; 7 (09) e015810
    CrossrefPubMedGoogle Scholar
  • 65 Kolarich AR, Shah JL, George Jr TJ. , et al. Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis. J Gastrointest Oncol 2018; 9 (03) 536-545
    CrossrefPubMedGoogle Scholar
  • 66 Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010; 90 (04) 817-837
    CrossrefPubMedGoogle Scholar
  • 67 Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer 2013; 119 (22) 3929-3942
    CrossrefPubMedGoogle Scholar
  • 68 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149 (06) 565-574
    CrossrefPubMedGoogle Scholar
  • 69 Spolverato G, Vitale A, Cucchetti A. , et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. Cancer 2015; 121 (22) 3998-4006
    CrossrefPubMedGoogle Scholar
  • 70 DeOliveira ML, Cunningham SC, Cameron JL. , et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245 (05) 755-762
    CrossrefPubMedGoogle Scholar
  • 71 Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI. What prognostic factors are important for resected intrahepatic cholangiocarcinoma?. J Gastroenterol Hepatol 2008; 23 (05) 766-770
    CrossrefPubMedGoogle Scholar
  • 72 Lang H, Sotiropoulos GC, Sgourakis G. , et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208 (02) 218-228
    CrossrefPubMedGoogle Scholar
  • 73 Valle J, Wasan H, Palmer DH. , et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedGoogle Scholar
  • 74 Eckel F, Schmid RM. Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Chemotherapy 2014; 60 (01) 13-23
    CrossrefPubMedGoogle Scholar
  • 75 Koay EJ, Odisio BC, Javle M, Vauthey J-N, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?. Hepatobiliary Surg Nutr 2017; 6 (02) 105-116
    CrossrefPubMedGoogle Scholar
  • 76 DeOliveira ML. Liver transplantation for cholangiocarcinoma: current best practice. Curr Opin Organ Transplant 2014; 19 (03) 245-252
    CrossrefPubMedGoogle Scholar
  • 77 Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 2002; 68 (04) 395-397
    CrossrefPubMedGoogle Scholar
  • 78 Genov I, Grigorov N, Mitova R, Golemanov B, Dinkov L. [Radiofrequency ablation of recurrent intrahepatic cholangiocarcinoma: a case report]. Khirurgiia (Sofiia) 2005; ••• (4-5): 45-47
    PubMedGoogle Scholar
  • 79 Rai R, Manas D, Rose J. Radiofrequency ablation of recurrent cholangiocarcinoma after orthotopic liver transplantation -- a case report. World J Gastroenterol 2005; 11 (04) 612-613
    PubMedGoogle Scholar
  • 80 Xu H-X, Wang Y, Lu M-D, Liu L-N. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 2012; 85 (1016): 1078-1084
    CrossrefPubMedGoogle Scholar
  • 81 Chiou YY, Hwang JI, Chou YH, Wang HK, Chiang JH, Chang CY. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 2005; 21 (07) 304-309
    CrossrefPubMedGoogle Scholar
  • 82 Carrafiello G, Laganà D, Cotta E. , et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol 2010; 33 (04) 835-839
    CrossrefPubMedGoogle Scholar
  • 83 Kim JH, Won HJ, Shin YM. , et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarci- noma. AJR Am J Roentgenol 2011; 196: W205–209
    PubMedGoogle Scholar
  • 84 Takahashi EA, Kinsman KA, Schmit GD. , et al. Thermal ablation of intrahepatic cholangiocarcinoma: safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY) 2018; 43 (12) 3487-3492
    CrossrefPubMedGoogle Scholar
  • 85 Yu MA, Liang P, Yu XL. , et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol 2011; 80 (02) 548-552
    CrossrefPubMedGoogle Scholar
  • 86 Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015; 26 (07) 943-948
    CrossrefPubMedGoogle Scholar
  • 87 Dhanasekaran R, Hemming AW, Zendejas I. , et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep 2013; 29 (04) 1259-1267
    CrossrefPubMedGoogle Scholar
  • 88 Tran Minh M, Mazzola A, Perdigao F, Charlotte F, Rousseau G, Conti F. Primary hepatic angiosarcoma and liver transplantation: radiological, surgical, histological findings and clinical outcome. Clin Res Hepatol Gastroenterol 2018; 42 (01) 17-23
    CrossrefPubMedGoogle Scholar
  • 89 Tsikopoulos K, Perdikakis E, Georgiannos D, Bisbinas I. Epithelioid hemangioma of the scapula treated with chemoembolization and microwave ablation: A case report. Acta Orthop Traumatol Turc 2018; 52 (02) 157-161
    CrossrefPubMedGoogle Scholar
  • 90 Yevich S, Calandri M, Gravel G. , et al. Reiterative radiofrequency ablation in the management of pediatric patients with hepatoblastoma metastases to the lung, liver, or bone. Cardiovasc Intervent Radiol 2019; 42 (01) 41-47
    CrossrefPubMedGoogle Scholar